With the development of carbapenemase inhibitors such as avibactam, relebactam and vaborbactam, it has become important to detect the type of carbapenemase produced for guiding antibiotic therapy. Among the several methods available for the same, we chose lateral flow assay (Resist-3 O. K. N., Coris BioConcepts, Gembloux, Belgium) and compared it against a commercially available molecular test (Xpert Carba R assay, version 2, Cepheid, Sunnyvale, CA, USA). Sixteen clinical isolates, which were resistant to carbapenems on phenotypic testing, were selected. Fourteen of these were Klebsiella pneumoniae and two were Escherichia coli a total of 22 carbapenemases. (OXA-48-14, New Delhi metallo-beta-lactamase [NDM]-7 and K. pneumoniae carbapenemase [KPC]-1) were detected by the Carba-R assay. Six isolates (K. pneumoniae-5 and E. coli-1) had co-production of OXA-48 and NDM. Resist-3 assay detected all twenty two enzymes. The distribution of enzymes in these 16 isolates was identical to that shown by the Carba-R (100% agreement). Hence, we conclude that lateral flow immunochromatography assay is a simple, rapid and cost-effective method for the detection of carbapenemases. This would help the clinician select the appropriate antibiotic and support antibiotic stewardship in the Indian settings.